^
Association details:
| Biomarker: | EGFRvIII mutation |
|---|---|
| Cancer: | Astrocytoma |
| Drug: | WSD0922 (EGFR inhibitor, EGFRvIII inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort.
Published date:
05/25/2023
Excerpt:
Among patients treated at MTD or higher dose levels and with available response data, 100% (5/5) of patients with NSCLC demonstrated clinical benefit (SD + PR) while 60% of patients had partial responses (intracranial and extracranial)….The MTD for WSD0922-Fu monotherapy is 160 mg BID. Preliminary efficacy was observed in patients with osimertinib-resistant NSCLC and EGFRvIII mutant HGA.
DOI:
10.1200/JCO.2023.41.16_suppl.3109
Trial ID:
